Eprosartan effects on intravascular platelet activity in patients with arterial hypertension and metabolic syndrome

Eprosartan effects on intravascular platelet activity in patients with arterial hypertension and metabolic syndrome

Aim: To study therapeutic effects of eprosartan on intravascular platelet activity in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods: In total, 32 participants received eprosartan (600 mg/d) for 4 months. Dynamics of lipid peroxidation in plasma and platel...

Full description

Bibliographic Details
Main Authors:	I. N. Medvedev, T. A. Kumova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2008-02-01
Series:	Российский кардиологический журнал
Subjects:	arterial hypertension metabolic syndrome platelets eprosartan
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/1525

Similar Items

Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2007-08-01)

Clinical effectiveness of eprosartan and hydroxyzine in patients with mild to moderate arterial hypertension and coexisting anxiety
by: G. V. Pogosova, et al.
Published: (2009-02-01)

THE EFFECTIVENESS OF CARVEDILOL AND EPROSARTAN IN PATIENTS WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE
by: R. L. Dashnamirov
Published: (2014-04-01)

Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
by: I. N. Medvedev, et al.
Published: (2007-06-01)

Intravascular platelet activity correction by fosinopril in arterial hypertension patients with metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2006-10-01)

Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2008-10-01)

Nebivolol therapy and reduction of intravascular platelet activity in patients with atrial hypertension and metabolic syndrome
by: I. N. Medvedev
Published: (2006-06-01)

Angiotensin receptor-1 antagonist eprosartan in patients with mild to moderate arterial hypertension
by: A. V. Shabalin, et al.
Published: (2005-12-01)

Rapid normalization of platelet hemostasis in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2008-04-01)

Increased intravascular platelet activity in metabolic syndrome patients, and its correction by simvastatin treatment
by: N. I. Gromnatsky, et al.
Published: (2004-12-01)

Pharmacogenetic aspects of eprosartan therapy and polymorphic markers of renin-angiotensin-aldosterone system genes in Uzbek patients with essential arterial hypertension
by: D. R. Kurbanova, et al.
Published: (2009-06-01)

Anti-remodeling efficacy of eprosartan in patients with essential hypertension, and gene polymorphism of angiotensin II type 1 receptors
by: B. Sh. Karimova, et al.
Published: (2005-02-01)

Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study
by: Radaideh, et al.
Published: (2011-08-01)

NonDpharmaceutical correction of intravascular platelet activity in hypertensive patients
by: I. N. Medvedev
Published: (2005-10-01)

Influence of additional risk factors on the antihypertensive efficacy of eprosartan and telmisartan in patients with essential hypertension
by: V. V. Syvolap, et al.
Published: (2017-12-01)

Оrganoprotective efficiency of eprosartan in patients with chronic glomerulonephritis
by: Ye. V. Kalyuzhina, et al.
Published: (2007-03-01)

Developing approaches to treating arterial hypertension in regard to possible pathways of angiotensin II synthesis
by: N. M. Chikhladze, et al.
Published: (2006-04-01)

The Effects of Eprosartan Mesylate and Lercanidipine on Reducing Microalbuminuria in Patients with Nephropathy due to Type 2 Diabetes
by: Botir T. Daminov, PhD, ScD, et al.
Published: (2013-06-01)

Organ-protective effect of fixed-dose combination antihypertensive therapy with eprosartan and hydrochlorothiazide for subclinical and clinical target organ damage in hypertensive patients
by: N A Koziolova, et al.
Published: (2012-12-01)

Arterial hypertension with stroke risk: clinical features, circadian blood pressure profiles, angiotensin II antagonist treatment
by: V. B. Simonenko, et al.
Published: (2005-06-01)

Еprosartan therapy effectiveness in arterial hypertension patients after stroke or transient ischemic attack
by: Yu. M. Pozdnyakov, et al.
Published: (2006-12-01)

PLATELET HEMOSTASIS DYNAMICS IN SIMVASTATINTREATED PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
by: I. N. Medvedev, et al.
Published: (2010-02-01)

Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate
by: Abdul Ahad, et al.
Published: (2017-11-01)

Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome
by: N. M. Krasnova, et al.
Published: (2008-06-01)

Verospiron effects on platelet aggregation in patients with arterial hypertension and abdominal obesity
by: I. N. Medvedev, et al.
Published: (2007-12-01)

Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome
by: O. N. Andreeva, et al.
Published: (2005-06-01)

CORRECTION OF AGGREGATIVE FUNCTION OF THE TROMBOCYTES IN ARTERIAL HYPERTENSION PATIENTS WITH METABOLIC SYNDROM UNDER THE INFLUENCE OF SIMVASTATINE
by: N. J. Gromnazky, et al.
Published: (2003-12-01)

Lisinopril effects on platelet activity in patients with arterial hypertension and impaired glucose tolerance
by: I. N. Medvedev, et al.
Published: (2008-06-01)

Prevalence of metabolic syndrome and its components in patients with arterial hypertension and obesity
by: I. E. Chazova, et al.
Published: (2005-12-01)

Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy
by: L. I. Abasova, et al.
Published: (2011-08-01)

Quantitative morphological characteristics of intravascular platelet activity in patients with diabetes mellitus type 2 with arterial hypertension under losartan treatment
by: Dzyak G.V., et al.
Published: (2012-01-01)

BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
by: V. A. Nevzorova, et al.
Published: (2015-12-01)

Pathogenesis of arterial hypertension within the metabolic syndrome
by: A S Ryazanov, et al.
Published: (2003-03-01)

Blood pressure lowering-based prevention and the POWER trial
by: Vladimir Anatolyevich Parfenov, et al.
Published: (2013-03-01)

Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
by: V. V. Trusov, et al.
Published: (2007-08-01)

Influence of combined antihypertensive therapy on plasmatic,vascular-thrombocytic hemostasis and lipid peroxidation in patientswith metabolic syndrome and arterial hypertension
by: N. M. Krasnova, et al.
Published: (2007-12-01)

P6.4 PLATELET ACTIVITY IN TEENAGE BOYS WITH PRIMARY ARTERIAL HYPERTENSION
by: Indre Bauziene*, et al.
Published: (2015-11-01)

P6.3 PLATELET ACTIVITY IN TEEN GIRLS WITH PRIMARY ARTERIAL HYPERTENSION
by: Indre Bauziene*, et al.
Published: (2015-11-01)

Relationship between metabolic syndrome components in patients with resistant arterial hypertension
by: I. P. Shmakova, et al.
Published: (2021-06-01)

Some hormonal systems in males with arterial hypertension and metabolic syndrome
by: A. N. Britov, et al.
Published: (2006-06-01)

Cannot write session to /tmp/vufind_sessions/sess_hcvq2e6mdrqpp6i7t3araienhc